Gamma Biosciences
Mirus bio produces transfection reagents, which are used in gene delivery.
Gamma Biosciences operates as a life sciences tool platform, focusing on advancing bioprocessing, gene therapy, and next-generation vaccines. The company serves biopharmaceutical innovators and manufacturers, providing them with the tools and technologies needed to deliver complex therapies to patients more quickly and efficiently. Gamma Biosciences operates in the biopharmaceutical market, which includes cell and gene therapies, vaccines, and biologics. The business model revolves around strategic investments and acquisitions, enhancing its portfolio and expanding its reach in the life sciences sector. Revenue is generated through the sale of advanced bioprocessing tools and technologies, as well as through strategic partnerships and investments in innovative companies. Recent acquisitions include controlling stakes in Mirus Bio and BioMagnetic Solutions, and investments in companies like Nirrin Technologies. These moves aim to bolster Gamma Biosciences' capabilities in gene therapy, next-generation vaccines, and continuous bioprocessing.
Keywords: bioprocessing, gene therapy, vaccines, biopharmaceutical, investments, acquisitions, life sciences, biomanufacturing, innovation, advanced therapies.